Goldman Sachs’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-55,438
| Closed | -$111K | – | 5339 |
|
|
2022
Q3 | $111K | Sell |
55,438
-247,763
| -82% | -$496K | ﹤0.01% | 4897 |
|
|
2022
Q2 | $225K | Buy |
303,201
+161,775
| +114% | +$120K | ﹤0.01% | 4849 |
|
|
2022
Q1 | $1.23M | Buy |
141,426
+2,815
| +2% | +$24.5K | ﹤0.01% | 3956 |
|
|
2021
Q4 | $2.22M | Buy |
138,611
+1,032
| +0.8% | +$16.5K | ﹤0.01% | 3435 |
|
|
2021
Q3 | $2.53M | Buy |
137,579
+1,317
| +1% | +$24.2K | ﹤0.01% | 3291 |
|
|
2021
Q2 | $1.9M | Sell |
136,262
-119,538
| -47% | -$1.67M | ﹤0.01% | 3551 |
|
|
2021
Q1 | $3.77M | Buy |
255,800
+214,179
| +515% | +$3.15M | ﹤0.01% | 2890 |
|
|
2020
Q4 | $807K | Buy |
41,621
+10,256
| +33% | +$199K | ﹤0.01% | 3573 |
|
|
2020
Q3 | $350K | Sell |
31,365
-20,593
| -40% | -$230K | ﹤0.01% | 3825 |
|
|
2020
Q2 | $703K | Buy |
51,958
+24,696
| +91% | +$334K | ﹤0.01% | 3429 |
|
|
2020
Q1 | $220K | Sell |
27,262
-4,284
| -14% | -$34.6K | ﹤0.01% | 3901 |
|
|
2019
Q4 | $303K | Buy |
31,546
+17,740
| +128% | +$170K | ﹤0.01% | 3852 |
|
|
2019
Q3 | $146K | Sell |
13,806
-8,171
| -37% | -$86.4K | ﹤0.01% | 3997 |
|
|
2019
Q2 | $253K | Buy |
21,977
+9,285
| +73% | +$107K | ﹤0.01% | 3778 |
|
|
2019
Q1 | $163K | Sell |
12,692
-3,505
| -22% | -$45K | ﹤0.01% | 3937 |
|
|
2018
Q4 | $100K | Buy |
+16,197
| New | +$100K | ﹤0.01% | 3888 |
|